CN116367831A - 用于治疗由kdm1a介导的疾病的药物配制品 - Google Patents

用于治疗由kdm1a介导的疾病的药物配制品 Download PDF

Info

Publication number
CN116367831A
CN116367831A CN202180068111.4A CN202180068111A CN116367831A CN 116367831 A CN116367831 A CN 116367831A CN 202180068111 A CN202180068111 A CN 202180068111A CN 116367831 A CN116367831 A CN 116367831A
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
amount
pharmaceutical
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068111.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·塔珀
C·切拉特卡
P·苏利亚克
P·维德
N·沃拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imago Biosciences Inc
Original Assignee
Imago Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imago Biosciences Inc filed Critical Imago Biosciences Inc
Publication of CN116367831A publication Critical patent/CN116367831A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180068111.4A 2020-10-01 2021-10-01 用于治疗由kdm1a介导的疾病的药物配制品 Pending CN116367831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
US63/086,353 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
CN116367831A true CN116367831A (zh) 2023-06-30

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068111.4A Pending CN116367831A (zh) 2020-10-01 2021-10-01 用于治疗由kdm1a介导的疾病的药物配制品

Country Status (10)

Country Link
US (1) US20230293495A1 (https=)
EP (1) EP4221704B1 (https=)
JP (1) JP7848195B2 (https=)
KR (1) KR20230079151A (https=)
CN (1) CN116367831A (https=)
AU (1) AU2021351536A1 (https=)
BR (1) BR112023005987A2 (https=)
CA (1) CA3193661A1 (https=)
MX (1) MX2023003783A (https=)
WO (1) WO2022072811A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
CN107427699A (zh) * 2015-02-12 2017-12-01 伊美格生物科学公司 用于治疗疾病的kdm1a抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
TW201431552A (zh) 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
CN111194306B (zh) * 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
KR20220113753A (ko) * 2019-12-09 2022-08-16 이마고 바이오사이언시즈 인코포레이티드 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
CN107427699A (zh) * 2015-02-12 2017-12-01 伊美格生物科学公司 用于治疗疾病的kdm1a抑制剂

Also Published As

Publication number Publication date
WO2022072811A1 (en) 2022-04-07
EP4221704A1 (en) 2023-08-09
KR20230079151A (ko) 2023-06-05
MX2023003783A (es) 2023-04-26
EP4221704A4 (en) 2024-11-06
BR112023005987A2 (pt) 2023-05-02
EP4221704B1 (en) 2025-09-24
JP2023544327A (ja) 2023-10-23
US20230293495A1 (en) 2023-09-21
JP7848195B2 (ja) 2026-04-20
CA3193661A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7187488B2 (ja) 固定用量製剤
EP3409272B1 (en) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
EP3675830A1 (en) High concentration dosage forms of pridopidine
US9572806B2 (en) Elution-stabilized preparation
CN103717209B (zh) 速释的含普拉格雷的稳定的口服药物组合物
KR20150059720A (ko) 아나글립틴 함유 제제
KR20180036633A (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
CN117695285A (zh) 一种jak激酶抑制剂药物组合物
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
US20260069569A1 (en) Ebselen containing oral dosage forms
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
EP4736851A1 (en) Levodopa-benserazide hydrochloride composition and preparation therefor
JP2025524357A (ja) 多数の顆粒
TWI921644B (zh) 固定劑量調配物
WO2026067737A1 (zh) 三唑类化合物的药物制剂及其制备方法
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
KR20200113116A (ko) 데페라시록스를 포함하는 필름코팅정제
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide
GB2480472A (en) Procarbazine hydrochloride capsules
IE86046B1 (en) A pharmaceutical formulation comprising procarbazine hydrochloride

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination